Filing summary
Issuer and period: The supplied filing is resTORbio, Inc. (Nasdaq: TORC), Form 10-Q for the quarter ended June 30, 2019, not Adicet Bio, Inc. The filing was signed August 14, 2019. Financial amounts below are in U.S. dollars.
Business context and reporting period
resTORbio was a clinical-stage biopharmaceutical company developing RTB101, a TORC1 inhibitor aimed at aging-related diseases. It had no product revenue and had devoted substantially all resources to research and development. The filing reports the three and six months ended June 30, 2019, compared with the same periods in 2018.
Financial results and liquidity
| Metric | Q2 2019 | Q2 2018 | Six months 2019 | Six months 2018 |
|---|---|---|---|---|
| Revenue | None | None | None | None |
| Research and development expense | $16.6 million | $11.8 million | $25.4 million | $20.0 million |
| General and administrative expense | $2.6 million | $2.3 million | $5.5 million | $4.4 million |
| Total operating expenses | $19.2 million | $14.1 million | $30.9 million | $24.3 million |
| Net loss | $18.3 million | $13.6 million | $29.4 million | $23.5 million |
| Basic and diluted loss per share | $0.51 | $0.48 | $0.91 | $0.95 |
As a pre-revenue company, operating and profit margins are not meaningful. Other income, primarily interest income, was $0.8 million in Q2 and $1.5 million for the first half of 2019. The company reported $132.8 million of cash, cash equivalents and marketable securities at June 30, 2019, including $21.4 million cash and cash equivalents and $111.4 million marketable securities. Current assets were $136.1 million; current liabilities were $9.7 million. Total liabilities were $9.7 million, with no debt or credit facility reported. Accumulated deficit was $100.8 million.
For the six months, operating cash use was $26.4 million, investing cash use was $9.7 million and financing cash inflow was $50.4 million. Cash and cash equivalents increased $14.3 million to $21.4 million. Financing included approximately $49.7 million net proceeds from the March-April public offering and $0.6 million from at-the-market sales.
Material changes versus prior comparable period
- Q2 operating expenses rose about 36% year over year, and the six-month total increased about 27%. Management attributed much of the R&D increase to clinical development activity and the start of Phase 3; Q2 R&D included a $2.5 million Novartis milestone payment.
- Six-month net loss increased by $6.0 million year over year. Loss per share improved for the six-month period, reflecting a larger weighted-average share count after equity issuance; Q2 loss per share worsened.
- Cash used in operations increased from $17.1 million to $26.4 million for the first half. The company raised approximately $49.7 million net through the 2019 public offering, compared with $89.9 million net from its 2018 IPO.
- Common shares issued and outstanding increased from 28.1 million at December 31, 2018 to 35.8 million at June 30, 2019, primarily from the offering and ATM sales.
Outlook, commentary, risks and unusual items
- Management expected available cash, equivalents and marketable securities to fund its operating plan through 2020, including the Phase 3 program and a potential NDA filing if the program succeeds. The filing cautions that this estimate depends on assumptions and capital could be used sooner than expected; elsewhere it states liquidity should cover at least the next twelve months from filing.
- PROTECTOR 1 had completed enrollment of 1,024 patients; top-line results were expected by early Q1 2020. PROTECTOR 2 was planned to begin in Q4 2019, with approximately 1,600 patients and results expected mid-2020.
- A Phase 1b/2a Parkinson’s disease trial of RTB101 alone or with sirolimus began in April 2019; data were expected in 2020. The company anticipated rising R&D and administrative spending and said further financing would be needed to advance its programs over the foreseeable future.
- Phase 2 results cited by management were encouraging, but Phase 3 efficacy and safety remained unproven. Risks include clinical and regulatory failure or delay, uncertain enrollment and trial costs, reliance on CROs and manufacturers, competition, intellectual-property protection, and potential inability to obtain additional funding on acceptable terms.
- The Novartis license includes up to $4.3 million in clinical milestones, up to $42 million in regulatory milestones, up to $125 million in commercial milestones, and tiered royalties. A $2.5 million clinical milestone was triggered in May 2019; no other remaining milestones or royalties had been reached by quarter-end.
- An amended Boston office lease began upon relocation on August 1, 2019, with a seven-year term and initial annual base rent of $0.6 million, increasing 2% annually; disclosed future minimum payments totaled $4.5 million. No material litigation was reported, and management reported disclosure controls effective at the reasonable-assurance level.
- After quarter-end, the company sold approximately 404,000 ATM shares through August 1, 2019, for $4.1 million net proceeds. The filing also reported $49.4 million remaining under the ATM agreement as of June 30, 2019.
Most important facts for investors to verify
- Confirm issuer identity: the supplied filing is resTORbio, not Adicet Bio.
- Track PROTECTOR 1 and 2 trial progress, results, safety findings, and whether stated reporting timelines are met.
- Compare actual cash burn and financing needs with management’s runway estimate; assess dilution from public and ATM equity sales.
- Review Novartis milestone and royalty obligations, the Parkinson’s trial, and the impact of the new lease on future commitments.
- Reconcile the reported quarter-end cash and securities balance with subsequent ATM proceeds and later filings.